{"transactions":[{"id":4614045,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-09T23:29:45.000Z","date":"2026-09-07","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":220000,"derivative":{"exercise_price":16.23,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001193125-26-386782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526386782/ownership.xml","form_type":"4"}},{"id":779034,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28367,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":66.3,"underlying":"Common Stock","underlying_shares":28367},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779033,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":52.66,"underlying":"Common Stock","underlying_shares":35472},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779032,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Cash-Out Option that had an exercise price per share that was equal to or greater than the Cash Amount, and less than the sum of (i) $41.00 (the Cash Amount) plus (ii) $4.00 (i.e., the maximum amount payable pursuant to a CVR assuming that the milestones are achieved) (such sum of $45.00, the \"Aggregate Amount\"), was automatically cancelled and converted into the right to receive one CVR for each share of Common Stock underlying such Cash-Out Option (with any payable milestone payment amounts being reduced by the excess, if any, of the applicable exercise price per share over the Cash Amount)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Cash-Out Option that had an exercise price per share that was equal to or greater than the Cash Amount, and less than the sum of (i) $41.00 (the Cash Amount) plus (ii) $4.00 (i.e., the maximum amount payable pursuant to a CVR assuming that the milestones are achieved) (such sum of $45.00, the \"Aggregate Amount\"), was automatically cancelled and converted into the right to receive one CVR for each share of Common Stock underlying such Cash-Out Option (with any payable milestone payment amounts being reduced by the excess, if any, of the applicable exercise price per share over the Cash Amount)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Cash-Out Option that had an exercise price per share that was equal to or greater than the Cash Amount, and less than the sum of (i) $41.00 (the Cash Amount) plus (ii) $4.00 (i.e., the maximum amount payable pursuant to a CVR assuming that the milestones are achieved) (such sum of $45.00, the \"Aggregate Amount\"), was automatically cancelled and converted into the right to receive one CVR for each share of Common Stock underlying such Cash-Out Option (with any payable milestone payment amounts being reduced by the excess, if any, of the applicable exercise price per share over the Cash Amount)."}],"balance_after":0,"derivative":{"exercise_price":44.9,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779031,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":35.46,"underlying":"Common Stock","underlying_shares":50974},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779030,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":115281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":29.76,"underlying":"Common Stock","underlying_shares":115281},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779029,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":19.39,"underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779028,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45220,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779027,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27320,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779026,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9754,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779025,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5645,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"(continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779024,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779023,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"}],"balance_after":41250,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779022,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24284,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. On May 11, 2026, the compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, which resulted in a payout percentage of 200% of target for each such Converted RSU Award, as reported in the table above. Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU 7. Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(continued from footnote 7) as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779021,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":24284,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. On May 11, 2026, the compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, which resulted in a payout percentage of 200% of target for each such Converted RSU Award, as reported in the table above. Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU 7. Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(continued from footnote 7) as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":24284,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779020,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45220,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. On May 11, 2026, the compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, which resulted in a payout percentage of 200% of target for each such Converted RSU Award, as reported in the table above. Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU 7. Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(continued from footnote 7) as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779019,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":45220,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return (\"TSR\") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index (\"Relative TSR\"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. On May 11, 2026, the compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, which resulted in a payout percentage of 200% of target for each such Converted RSU Award, as reported in the table above. Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU 7. Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(continued from footnote 7) as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":45220,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779018,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding RSU that was not a Cash-Out RSU Award (each, a \"Converted RSU Award\") that was subject to both a time-based and a performance-based vesting schedule (other than RSUs granted in January 2026 and for which performance-based vesting schedule was based on total shareholder return), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the target level of performance, multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779017,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":22610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding RSU that was not a Cash-Out RSU Award (each, a \"Converted RSU Award\") that was subject to both a time-based and a performance-based vesting schedule (other than RSUs granted in January 2026 and for which performance-based vesting schedule was based on total shareholder return), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the target level of performance, multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting."}],"balance_after":22610,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":779016,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T23:25:38.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":116338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526224604/ownership.xml","form_type":"4"}},{"id":926959,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-30T21:08:37.000Z","date":"2026-01-28","kind":"grant","planned":false,"acquired":true,"shares":45220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service."}],"balance_after":116338,"source":{"system":"sec-edgar","filing":"0001492422-26-000074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000149242226000074/form4.xml","form_type":"4"}},{"id":932255,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-23T21:08:15.000Z","date":"2026-01-22","kind":"sale","planned":false,"acquired":false,"shares":7725,"price":21.7654,"value":168137.715,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026."}],"balance_after":71118,"source":{"system":"sec-edgar","filing":"0001492422-26-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000149242226000056/form4.xml","form_type":"4"}},{"id":934176,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:12:14.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":2203,"price":19.7929,"value":43603.7587,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026."}],"balance_after":78843,"source":{"system":"sec-edgar","filing":"0001492422-26-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000149242226000040/form4.xml","form_type":"4"}},{"id":938451,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:30:08.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":2618,"price":22.1872,"value":58086.0896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 12, 2026."}],"balance_after":81046,"source":{"system":"sec-edgar","filing":"0001492422-26-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000149242226000027/form4.xml","form_type":"4"}},{"id":1114869,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T20:24:10.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":19.39,"value":1599675.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service."}],"balance_after":82500,"derivative":{"exercise_price":19.39,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001127602-25-017281","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225017281/form4.xml","form_type":"4"}},{"id":1290751,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-30T17:13:56.000Z","date":"2025-01-29","kind":"sale","planned":false,"acquired":false,"shares":825,"price":29.5236,"value":24356.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 28, 2025."}],"balance_after":83664,"source":{"system":"sec-edgar","filing":"0001127602-25-002383","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225002383/form4.xml","form_type":"4"}},{"id":1296330,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-23T20:31:08.000Z","date":"2025-01-22","kind":"sale","planned":false,"acquired":false,"shares":3948,"price":30.4255,"value":120119.874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2025."}],"balance_after":84489,"source":{"system":"sec-edgar","filing":"0001127602-25-001841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225001841/form4.xml","form_type":"4"}},{"id":1298758,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-21T21:09:04.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":36426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service."}],"balance_after":88437,"source":{"system":"sec-edgar","filing":"0001127602-25-001625","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225001625/form4.xml","form_type":"4"}},{"id":1298757,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-21T21:09:04.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":2145,"price":29.9582,"value":64260.339,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025."}],"balance_after":52011,"source":{"system":"sec-edgar","filing":"0001127602-25-001625","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225001625/form4.xml","form_type":"4"}},{"id":1303440,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-14T21:22:49.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":2632,"price":28.7021,"value":75543.9272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes 501 shares from April 30, 2024 ESPP purchase."}],"balance_after":54156,"source":{"system":"sec-edgar","filing":"0001127602-25-001201","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760225001201/form4.xml","form_type":"4"}},{"id":1576648,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-14T20:17:21.000Z","date":"2024-03-13","kind":"sale","planned":false,"acquired":false,"shares":3452,"price":58.1335,"value":200676.842,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $57.92 - $58.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":56287,"source":{"system":"sec-edgar","filing":"0001127602-24-010127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224010127/form4.xml","form_type":"4"}},{"id":1576647,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-14T20:17:21.000Z","date":"2024-03-13","kind":"sale","planned":false,"acquired":false,"shares":7768,"price":57.307,"value":445160.776,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $56.91 - $57.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":59739,"source":{"system":"sec-edgar","filing":"0001127602-24-010127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224010127/form4.xml","form_type":"4"}},{"id":1665126,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-31T21:31:31.000Z","date":"2024-01-29","kind":"sale","planned":false,"acquired":false,"shares":835,"price":64.1382,"value":53555.397,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024."}],"balance_after":67507,"source":{"system":"sec-edgar","filing":"0001127602-24-002746","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224002746/form4.xml","form_type":"4"}},{"id":1672975,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-23T23:11:00.000Z","date":"2024-01-22","kind":"sale","planned":false,"acquired":false,"shares":2593,"price":64.996,"value":168534.628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/19/2024."}],"balance_after":68342,"source":{"system":"sec-edgar","filing":"0001127602-24-001953","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224001953/form4.xml","form_type":"4"}},{"id":1677849,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-17T21:40:13.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":28367,"price":66.3,"value":1880732.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service."}],"balance_after":28367,"derivative":{"exercise_price":66.3,"expiration_date":"2034-01-15","underlying":"Common Stock","underlying_shares":28367},"source":{"system":"sec-edgar","filing":"0001127602-24-001437","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224001437/form4.xml","form_type":"4"}},{"id":1677848,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-17T21:40:13.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":1857,"price":66.8086,"value":124063.5702,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024."}],"balance_after":70935,"source":{"system":"sec-edgar","filing":"0001127602-24-001437","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224001437/form4.xml","form_type":"4"}},{"id":1677847,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-17T21:40:13.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":19508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service."}],"balance_after":72792,"source":{"system":"sec-edgar","filing":"0001127602-24-001437","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760224001437/form4.xml","form_type":"4"}},{"id":1777292,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T21:03:18.000Z","date":"2023-09-18","kind":"exercise","planned":false,"acquired":false,"shares":9719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option was granted on August 17, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service."}],"balance_after":115281,"derivative":{"exercise_price":29.76,"expiration_date":"2030-08-16","underlying":"Common Stock","underlying_shares":9719},"source":{"system":"sec-edgar","filing":"0001127602-23-024445","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223024445/form4.xml","form_type":"4"}},{"id":1777291,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-09-19T21:03:18.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":10631,"price":46.147,"value":490588.757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $46.140 - $46.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This includes 412 shares from 04/30/2023 ESPP purchase."}],"balance_after":53284,"source":{"system":"sec-edgar","filing":"0001127602-23-024445","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223024445/form4.xml","form_type":"4"}},{"id":1777290,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-09-19T21:03:18.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":9719,"price":42.2085,"value":410224.4115,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $46.200 - $46.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":63915,"source":{"system":"sec-edgar","filing":"0001127602-23-024445","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223024445/form4.xml","form_type":"4"}},{"id":1777289,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-09-19T21:03:18.000Z","date":"2023-09-18","kind":"exercise","planned":false,"acquired":true,"shares":9719,"price":29.76,"value":289237.44,"ownership":{"direct":true},"balance_after":73634,"source":{"system":"sec-edgar","filing":"0001127602-23-024445","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223024445/form4.xml","form_type":"4"}},{"id":1999764,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-22T11:45:14.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":14023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Reporting Person was granted performance-based stock options on January 21, 2022, the vesting of which was subject to the attainment of the 2022 Performance Condition. On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 25% of the shares underlying the option. The remaining shares underlying the option vest in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service."}],"balance_after":14023,"derivative":{"exercise_price":35.46,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":14023},"source":{"system":"sec-edgar","filing":"0000899243-23-005786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000089924323005786/doc4.xml","form_type":"4"}},{"id":1999763,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-02-22T11:45:14.000Z","date":"2023-02-21","kind":"tax_withholding","acquired":false,"shares":825,"price":58.5,"value":48262.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of PRSUs."}],"balance_after":63503,"source":{"system":"sec-edgar","filing":"0000899243-23-005786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000089924323005786/doc4.xml","form_type":"4"}},{"id":1999762,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-02-22T11:45:14.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":9886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted performance-based restricted stock units (\"PRSUs\") on January 21, 2022, the vesting of which was subject to the attainment of each of the following events: (i) the submission of a new drug application (\"NDA\") for intravitreal pegcetacoplan with the U.S. Food and Drug Administration (\"FDA\") for the treatment of geographic atrophy secondary to age-related macular degeneration in the second quarter of 2022; (ii) the acceptance of such NDA with priority review by the FDA; and (iii) receipt of approval of the NDA by the FDA by March 15, 2023 (collectively, the \"2022 Performance Condition\"). On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 2,471 shares of common stock, representing 25% of the shares underlying the PRSUs.  The remaining shares underlying the PRSUs vest as to 25% on each anniversary of the grant date thereafter, subject to continued service."}],"balance_after":64328,"source":{"system":"sec-edgar","filing":"0000899243-23-005786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000089924323005786/doc4.xml","form_type":"4"}},{"id":2042116,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-30T22:02:27.000Z","date":"2023-01-27","kind":"tax_withholding","acquired":false,"shares":551,"price":52.77,"value":29076.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares withheld for tax on a restricted stock unit release."}],"balance_after":54442,"source":{"system":"sec-edgar","filing":"0001127602-23-002687","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223002687/form4.xml","form_type":"4"}},{"id":2047435,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-24T22:21:50.000Z","date":"2023-01-20","kind":"tax_withholding","acquired":false,"shares":2034,"price":52.05,"value":105869.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares withheld for tax on a restricted stock unit release."}],"balance_after":54993,"source":{"system":"sec-edgar","filing":"0001127602-23-002133","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223002133/form4.xml","form_type":"4"}},{"id":2053747,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-18T00:41:14.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":35472,"price":52.66,"value":1867955.52,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This represents a stock option award granted 01/12/2023 that vest over a four year period.  25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service."}],"balance_after":35472,"derivative":{"exercise_price":52.66,"expiration_date":"2033-01-11","underlying":"Common Stock","underlying_shares":35472},"source":{"system":"sec-edgar","filing":"0001127602-23-001499","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223001499/form4.xml","form_type":"4"}},{"id":2053746,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-18T00:41:14.000Z","date":"2022-04-25","kind":"other","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the cancellation of a performance stock option granted on 01/28/2021. The performance metrics were not met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service."}],"balance_after":0,"derivative":{"exercise_price":44.9,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001127602-23-001499","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223001499/form4.xml","form_type":"4"}},{"id":2053745,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-18T00:41:14.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":22580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This represents a Restricted Stock Award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This includes 763 shares from the 04/29/22 ESPP purchase and 4 shares from the 10/31/22 ESPP purchase."}],"balance_after":57027,"source":{"system":"sec-edgar","filing":"0001127602-23-001499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223001499/form4.xml","form_type":"4"}},{"id":2053744,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-18T00:41:14.000Z","date":"2022-04-25","kind":"other","acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met."}],"balance_after":33680,"source":{"system":"sec-edgar","filing":"0001127602-23-001499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760223001499/form4.xml","form_type":"4"}},{"id":2419185,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-02-01T23:06:59.000Z","date":"2022-01-28","kind":"tax_withholding","acquired":false,"shares":650,"price":38.59,"value":25083.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents shares used to cover tax withholding on a Restricted Stock Unit release."}],"balance_after":35555,"source":{"system":"sec-edgar","filing":"0001127602-22-002812","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760222002812/form4.xml","form_type":"4"}},{"id":2426729,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-25T21:51:36.000Z","date":"2022-01-21","kind":"grant","acquired":true,"shares":36951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service."}],"balance_after":36951,"derivative":{"exercise_price":35.46,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":36951},"source":{"system":"sec-edgar","filing":"0001127602-22-002062","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760222002062/form4.xml","form_type":"4"}},{"id":2426728,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-01-25T21:51:36.000Z","date":"2022-01-21","kind":"grant","acquired":true,"shares":26051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes 758 shares from 04/30/21 ESPP Purchase and 21 shares from 10/29/21 ESPP Purchase."}],"balance_after":36205,"source":{"system":"sec-edgar","filing":"0001127602-22-002062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760222002062/form4.xml","form_type":"4"}},{"id":2888595,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:38:14.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service."}],"balance_after":11250,"derivative":{"exercise_price":44.9,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001127602-21-003237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760221003237/form4.xml","form_type":"4"}},{"id":2888594,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:38:14.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service."}],"balance_after":45000,"derivative":{"exercise_price":44.9,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001127602-21-003237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760221003237/form4.xml","form_type":"4"}},{"id":2888593,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-02-01T21:38:14.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Performance Unit grant will vest 25% annually over four years from grant date, subject to the satisfaction of a specified performance condition and continued service."}],"balance_after":9375,"source":{"system":"sec-edgar","filing":"0001127602-21-003237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760221003237/form4.xml","form_type":"4"}},{"id":2888592,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-02-01T21:38:14.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Restricted Stock Units grant will vest 25% annually over four years from grant date, subject to continued service."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001127602-21-003237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492422/000112760221003237/form4.xml","form_type":"4"}}]}